Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.52 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.49 |
| ▸ | TEK | Q02763 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.46 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | MPL | P40238 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1323687 | 0.84 | MAPT (0.53) | KDRMEN1NPC1RAB9AKMT2A | |
| SCHEMBL24178149 | 0.81 | — | — | |
| SCHEMBL30062475 | 0.80 | MEN1 (0.67) | MEN1NPC1RAB9AKMT2A | |
| SCHEMBL30046984 | 0.79 | KDR (0.54) | SCN9ASCN5AKDRERBB2TEK | |
| SCHEMBL14843891 | 0.77 | MKNK1 (0.49) | KDRMPL | |
| SCHEMBL30046349 | 0.76 | SCN9A (0.76) | SCN9ASCN5AKDRERBB2TEK | |
| SCHEMBL16144467 | 0.75 | ALDH1A1 (0.54) | KDRERBB2MEN1RAB9AKMT2A | |
| SCHEMBL15522350 | 0.75 | SCN9A (0.59) | SCN9ASCN5AKDRERBB2TEK | |
| SCHEMBL3487003 | 0.75 | MEN1 (0.61) | SCN9ASCN5AKDRTEKMEN1 | |
| SCHEMBL2174012 | 0.75 | SCN9A (0.61) | SCN9ASCN5AKDRTEKMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161304-A1 | Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | MERCK PATENT GMBH (DE) | 2025-05-22 | — | — | US | disclosed |
| US-11491153-B2 | Methods for treating cancer using pyrimidine and pyridine compounds with BTK inhibitory activity | MERCK PATENT GMBH (DE) | 2022-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161304-A1 | Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | BTK, SYK, LCK | SCN9A 4436/4885SCN5A 4402/4885KDR 1059/4885 |
| US-11491153-B2 | Methods for treating cancer using pyrimidine and pyridine compounds with BTK inhibitory activity | BTK, SYK, LCK | SCN9A 4436/4885SCN5A 4402/4885KDR 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.